Blood Test Developed to Detect Breast Cancer
By LabMedica International staff writers Posted on 12 May 2014 |

Image: The Octava blood tests, developed for rapid, accurate detection of breast cancer tumors (Photo courtesy of Eventus Diagnostics).
A simple blood test has been developed as an easy, noninvasive method to detect breast cancer and is designed to be used in conjunction with annual screening mammograms.
The developed assay has been described as an accurate, cost-effective, immune system-based means of detection by measuring breast cancer-specific autoantibodies to detect the presence or absence of breast cancer.
The blood test has been validated by clinical studies conducted at cancer centers in the USA, Israel, and Italy that analyzed blood samples from over 800 women. The women in the trial all had positive mammograms and their breast cancer pathologies were verified by biopsy. The test measures cancer-specific antibodies produced by the immune system in response to the growth of tumors, and can be used both to quickly diagnose breast cancer before tumors become visible in mammogram, as well as identify false negative and false positive mammogram results.
The Octava tests were developed by Eventus Diagnostics’ subsidiary (Moshav Ora, Israel) and the two chip-based tests, called Octava Pink and Octava Blue, require the patient to donate a small sample of plasma to quickly determine the presence of the antibodies. The Octava Blue test is designed for use in conjunction with screening mammograms to provide additional diagnostic information to help physicians confirm true abnormal mammography results with high accuracy, while also helping to reduce the large number of unnecessary biopsies caused by false positive results.
The Octava Pink test is designed to provide additional diagnostic information to help physicians confirm true negative mammography findings with high accuracy, while helping to identify the presence of cancer in more than half of the cases where mammography produces a false negative result and cancer is actually present. The Octava Pink test can also provide additional information to address the estimated 5% of core needle breast biopsy results that represent false negative findings. The information from Octava Pink could help physicians detect at least half of those cases where cancer is actually present, possibly triggering an additional biopsy. Octava Pink may also be useful to physicians caring for women who will not or cannot receive mammograms.
Marvin M. Rosenberg, DDS, the president of Eventus Diagnostics, said, “The tests could be used by women with dense breast tissue who received normal mammogram results, or by women hoping to detect tumor cells without exposing themselves to radiation. Over 30% of breast cancer cases in women with dense breast tissue are missed by mammograms, a gap Eventus’ technology aims to address.” Eventus recently secured USD 2.72 million in funding to finance a large clinical study of the Octava tests to support its application for US Food and Drug Administration (FDA; Silver Spring, MD, USA) clearance.
Related Links:
Eventus Diagnostics
US Food and Drug Administration
The developed assay has been described as an accurate, cost-effective, immune system-based means of detection by measuring breast cancer-specific autoantibodies to detect the presence or absence of breast cancer.
The blood test has been validated by clinical studies conducted at cancer centers in the USA, Israel, and Italy that analyzed blood samples from over 800 women. The women in the trial all had positive mammograms and their breast cancer pathologies were verified by biopsy. The test measures cancer-specific antibodies produced by the immune system in response to the growth of tumors, and can be used both to quickly diagnose breast cancer before tumors become visible in mammogram, as well as identify false negative and false positive mammogram results.
The Octava tests were developed by Eventus Diagnostics’ subsidiary (Moshav Ora, Israel) and the two chip-based tests, called Octava Pink and Octava Blue, require the patient to donate a small sample of plasma to quickly determine the presence of the antibodies. The Octava Blue test is designed for use in conjunction with screening mammograms to provide additional diagnostic information to help physicians confirm true abnormal mammography results with high accuracy, while also helping to reduce the large number of unnecessary biopsies caused by false positive results.
The Octava Pink test is designed to provide additional diagnostic information to help physicians confirm true negative mammography findings with high accuracy, while helping to identify the presence of cancer in more than half of the cases where mammography produces a false negative result and cancer is actually present. The Octava Pink test can also provide additional information to address the estimated 5% of core needle breast biopsy results that represent false negative findings. The information from Octava Pink could help physicians detect at least half of those cases where cancer is actually present, possibly triggering an additional biopsy. Octava Pink may also be useful to physicians caring for women who will not or cannot receive mammograms.
Marvin M. Rosenberg, DDS, the president of Eventus Diagnostics, said, “The tests could be used by women with dense breast tissue who received normal mammogram results, or by women hoping to detect tumor cells without exposing themselves to radiation. Over 30% of breast cancer cases in women with dense breast tissue are missed by mammograms, a gap Eventus’ technology aims to address.” Eventus recently secured USD 2.72 million in funding to finance a large clinical study of the Octava tests to support its application for US Food and Drug Administration (FDA; Silver Spring, MD, USA) clearance.
Related Links:
Eventus Diagnostics
US Food and Drug Administration
Latest Immunology News
- World’s First Clinical Test Predicts Best Rheumatoid Arthritis Treatment
- Blood Test Detects Organ Rejection in Heart Transplant Patients
- Liquid Biopsy Approach to Transform Diagnosis, Monitoring and Treatment of Lung Cancer
- Computational Tool Exposes Hidden Cancer DNA Changes Influencing Treatment Resistance
- New Tool Detects Breast Cancer Relapses Five Years in Advance
- T Cells in Blood Can Detect Parkinson's Years Before Diagnosis
- POC Diagnostic Platform Performs Immune Analysis Using One Drop of Fingertip Blood
- Treatment Switching Guided by Liquid Biopsy Blood Tests Improves Outcomes for Breast Cancer Patients
- First-Of-Its-Kind Device Profiles Newborns' Immune Function Using Single Blood Drop
- Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
- Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
- Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions
- Cerebrospinal Fluid Test Predicts Dangerous Side Effect of Cancer Treatment
- New Test Measures Preterm Infant Immunity Using Only Two Drops of Blood
- Simple Blood Test Could Help Choose Better Treatments for Patients with Recurrent Endometrial Cancer
- Novel Analytical Method Tracks Progression of Autoimmune Diseases
Channels
Clinical Chemistry
view channel
New Clinical Chemistry Analyzer Designed to Meet Growing Demands of Modern Labs
A new clinical chemistry analyzer is designed to provide outstanding performance and maximum efficiency, without compromising affordability, to meet the growing demands of modern laboratories.... Read more
New Reference Measurement Procedure Standardizes Nucleic Acid Amplification Test Results
Nucleic acid amplification tests (NAATs) play a key role in diagnosing a wide range of infectious diseases. These tests are generally known for their high sensitivity and specificity, and they can be developed... Read moreMolecular Diagnostics
view channel
Newly-Cleared Technology a Game Changer for Diagnosis of Lyme Disease
Lyme disease is one of the fastest-growing infectious diseases, with approximately 476,000 cases diagnosed annually in the United States. The symptoms of Lyme disease, such as fever, headache, fatigue,... Read more
Innovative Liquid Biopsy Test Uses RNA to Detect Early-Stage Cancer
Detecting and diagnosing cancer, particularly in its early stages, remains a significant challenge. Liquid biopsies offer a promising non-invasive alternative to traditional biopsies, which require removing... Read moreHematology
view channel
Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results
Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more
First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes
Heparin dosing requires careful management to avoid both bleeding and clotting complications. In high-risk situations like extracorporeal membrane oxygenation (ECMO), mortality rates can reach about 50%,... Read moreImmunology
view channel
World’s First Clinical Test Predicts Best Rheumatoid Arthritis Treatment
Rheumatoid arthritis (RA) is a chronic condition affecting 1 in 100 people in the UK today, causing the immune system to attack its joints. Unlike osteoarthritis, which is caused by wear and tear, RA can... Read more
Blood Test Detects Organ Rejection in Heart Transplant Patients
Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Liquid Biopsy Approach to Transform Diagnosis, Monitoring and Treatment of Lung Cancer
Lung cancer continues to be a major contributor to cancer-related deaths globally, with its biological complexity and diverse regulatory processes making diagnosis and treatment particularly difficult.... Read more
Computational Tool Exposes Hidden Cancer DNA Changes Influencing Treatment Resistance
Structural changes in tumor DNA are among the most damaging genetic alterations in cancer, yet they often go undetected, particularly when tissue samples are degraded or of low quality. These hidden genomic... Read moreMicrobiology
view channel
Viral Load Tests Can Help Predict Mpox Severity
Mpox is a viral infection that causes flu-like symptoms and a characteristic rash, which evolves significantly over time and varies between patients. The disease spreads mainly through direct contact with... Read more
Gut Microbiota Analysis Enables Early and Non-Invasive Detection of Gestational Diabetes
Gestational diabetes mellitus is a common metabolic disorder marked by abnormal glucose metabolism during pregnancy, typically emerging in the mid to late stages. It significantly heightens the risk of... Read moreTechnology
view channel
Low-Cost Biosensing Technology Detects Disease Biomarkers in Minutes
Rapid at-home tests for diseases like COVID-19 have become increasingly popular for their convenience, but they come with a major drawback: they are less sensitive than the tests performed in medical settings.... Read more
AI Tool Could Help Identify Specific Gut Bacterial Targets for Treatment of Diseases
The human body hosts trillions of bacteria, particularly in the gut, which have a significant role in digestion and various other aspects of health. These gut bacteria produce a variety of metabolites... Read moreIndustry
view channel
Quanterix Completes Acquisition of Akoya Biosciences
Quanterix Corporation (Billerica, MA, USA) has completed its previously announced acquisition of Akoya Biosciences (Marlborough, MA, USA), paving the way for the creation of the first integrated solution... Read more
Lunit and Microsoft Collaborate to Advance AI-Driven Cancer Diagnosis
Lunit (Seoul, South Korea) and Microsoft (Redmond, WA, USA) have entered into a collaboration to accelerate the delivery of artificial intelligence (AI)-powered healthcare solutions. In conjunction with... Read more